TH79012A - Oral dosage mixtures with stable dose restricted release. - Google Patents

Abstract

DC60 (24/01/44), a solid oral dose-restricted mixed-release compound, was film-coated with a nasal congestion reliever. Sudo e feedrine Or the salts of them, such as sudo, feedrine, sulfate. In the core with Results: To provide the maximum geometrical plasma concentration of Sudo ephedrine approximately 345 ng / ml to approx 365 ng / ml. At approximately 7.60 hours to approximately 8.40 hours and the coating That is two or three films coated on this core The second coating contains the amount of the non-sedative antihistamine, desloratadine. Effective to provide the maximum geometrical plasma concentration of desloratadine approximately 2.15 ng / ml to approx 2.45 ng / ml. It took approximately 4.0 hours to approximately 4.5 hours and the use of the mixture for treatment of patients showing associated indications and symptoms. With conditions of allergy-related diseases And / or in relation to skin inflammation And the air passage was disclosed. A solid oral dose-restricted mixture was coated with a film with a nasal congestion reducing agent. Sudo e feedrine Or the salts of them like sudo, ephidine, sulphate In the core with Results: To provide the maximum geometrical plasma concentration of Sudo ephedrine approximately 345 ng / ml to approx 365 ng / ml. At approximately 7.60 hours to approximately 8.40 hours and the coating That is two or three films coated on this core The second coating contains the amount of the non-sedative antihistamine, desloratadine. Effective to provide the maximum geometrical plasma concentration of desloratadine approximately 2.15 ng / ml to approx 2.45 ng / ml. It took approximately 4.0 hours to approximately 4.5 hours and the use of the mixture for treatment of patients showing associated indications and symptoms. With conditions of allergy-related diseases And / or in relation to skin inflammation And the air passageway has been disclosed for a drug patent.

Claims (1)

1. A solid orally-restricted, finely-released, film-coated mixture of doses consisting of (a) a core containing an effective amount of sudoephrene or salt of These things that And (b) a film-based coating that covers the nocturnal core regularly and contains effective amounts of desloratadine. The pharmacologically acceptable amounts of sudo ephirene, or salts, have been shown to produce the highest geometrical plasma concentrations of about 345 nanograms of sudo ephedrine. Tag: drug patent